AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Delisting risk

CTOR · NASDAQ · Medical - Pharmaceuticals

Citius Oncology

Commercializing LYMPHIR for relapsed or refractory cutaneous T-cell lymphoma.

$0.7756

After-hours close−0.01 (−1.50%)

At close$0.7874(−0.37%)

Something off on this page? Send us feedback.

Profile

Citius Oncology, Inc.CTORHealth Care

Commercializes LYMPHIR, an IL-2-receptor-directed therapy for relapsed or refractory cutaneous T-cell lymphoma after prior systemic treatment. The portfolio centers on this first commercial product, launched in the United States, while Citius Pharmaceuticals remains majority owner and provides shared management services.

Commercializes LYMPHIR, an IL-2-receptor-directed therapy for adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma after prior systemic treatment. Launched in the United States in December 2025, LYMPHIR is the first commercial product and the portfolio’s central asset.

The company was formed by Citius Pharmaceuticals to hold LYMPHIR-related assets, and its Nasdaq-listed security resulted from a merger with TenX Keane Acquisition. Citius Pharmaceuticals remains the majority owner and provides shared management services.

Commercial revenue began with the LYMPHIR launch. Operating losses since inception, historical financing from Citius Pharmaceuticals, and limited post-launch revenue remain structural features of this early commercial stage.

Company facts

CEOLeonard Mazur

ListedAug 13, 2024

ExchangeNASDAQ

HeadquartersCranford, NJ

CountryUnited States

Employees285

CIK0001851484

ISINUS17331Y1091

Key statistics

Market cap$72.1M

EPS (ttm)−$0.4777

P/E (ttm)−1.62

ROE-103.0%

P/B2.07

P/S10.15

Dividend yield—

Beta1.97vs XLV 0.42

Year to date −27.1% · Average volume (30d) 111.8K

Analysts

Price target, next 12 months$6.00+669.2%Median of 2 analysts · vs the Aug 28 close

ConsensusBuy2 of 2 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $0.7800

High$6.00+669.2%

Median$6.00+669.2%

Low$6.00+669.2%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior rating	Rating	Target
Sep 23, 2025	Maxim Group	Upgrade	Hold	Buy	$6
May 23, 2025	Maxim Group	Downgrade	Buy	Hold

Earnings

EPS

Estimate−$0.07

Reported−$0.08−14.3%

Revenue

Estimate$2.5M

Reported$1.5M−40.2%

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 14, 2026Q3 FY26	−$0.07	−$0.08	−14.3%	$2.5M	$1.5M	−40.2%	+10.04%
May 15, 2026Q2 FY26	−$0.01	−$0.27	−2,600.0%	$7.0M	$1.7M	−76.2%	−13.95%
Feb 13, 2026Q1 FY26	−$0.04	−$0.06	−50.0%	$4.4M	$3.9M	−9.8%	−3.28%
Dec 23, 2025Q4 FY25	−$0.06	−$0.06	0.0%	—	—	—	−9.45%

View details

Financial highlights

	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26
Revenue	$0	$0	$0	$3.9M	$1.7M	$1.5M
Gross profit	$0	$0	$0	$3.2M	$1.3M	−$718.4K
Operating income	−$7.5M	−$4.9M	−$4.7M	−$5.3M	−$28.6M	−$8.7M
Net income	−$7.7M	−$5.4M	−$5.0M	−$5.5M	−$26.6M	−$8.9M
Diluted EPS	−$0.11	−$0.08	−$0.06	−$0.06	−$0.27	−$0.08
Gross margin	—	—	—	80.0%	80.3%	-48.1%
Operating margin	—	—	—	-133.2%	-1,716.2%	-583.5%

Fiscal years (4-quarter sums)FY23 $0 · FY24 $0 · FY25 $0

Balance sheet, Jun 30, 2026Cash & short-term investments $16.6M · Total debt $10.2M · Total assets $112.1M · Shareholders' equity $40.4M

Dividends

No dividends on record.

Ownership

Institutions 15.32%14.25M sharesInsiders 6.58%6.12M sharesOther 78.10%72.61M shares

Shares outstanding 92.98M · Float 17.72M · 19.1% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Armistice Capital, LLC	9.30M	9.99%	13G	May 15, 2026
Bank of America Corp /DE/	3.84M	4.12%	13F	May 18, 2026
Leonard L. Mazur · director, officer: Chief Executive Officer	1.70M	1.83%	Form 4	Sep 23, 2025
Myron Z. Holubiak · director, officer: Secretary	950.0K	1.02%	Form 4	Sep 23, 2025
Jaime Bartushak · officer: Chief Financial Officer	825.0K	0.89%	Form 4	Sep 23, 2025

Insider tradesForm 4

No open-market trades in the last 12 months.